are antibiotics,8 fungicides,9 antiulceretics,10 antidiabetics, an-
tihypertensive, and anti-inflammatory agents.1b,11 Imidazole-
based drugs such as cimetidine, etomidate, and ketoconazole
are currently in clinical use.1b,12 Recent advances in the
imidazole-tailored ionic liquids (e.g., refs 1b, 13), stable
nucleophilic carbenes (e.g., refs 14a-d), and organic catalysts11,15
are other applications of imidazole derivatives.
Consequently, efforts are focused on the development of
methodologies for the synthesis and functionalization of imi-
dazoles. 2-Vinylimidazoles are of interest as potent building
blocks for synthesis of novel imidazole derivatives. 2-Vinylimi-
dazoles were obtained by vapor-phase (300-1000 °C) catalytic
dehydrogenation of 2-ethylimidazoles, the crude product being
a mixture of target and starting compounds.16 2-Vinylimidazole
and 1-methyl-2-vinylimidazole were also prepared by the
dehydration of the corresponding 2-hydroxyethylimidazoles in
12% yield.17 1-Methyl-2-(1-phenylethenyl)-1H-imidazole was
obtained by dehydration of the 2-(1-hydroxy-1-phenylethyl)
derivatives (in 73-80% yield).18 2-Vinylimidazoles having ester
and cyano functions in the vinyl group were synthesized from
1H-imidazole-2-carbaldehyde and active methylene com-
pounds.19 The Wittig reaction with 2-chloromethylbenzimida-
zoles led to 2-vinylbenzimidazoles.20 From 1-alkylimidazole-
2-carbaldehydes and tribenzylphosphine oxide (Wittig-Horner
reaction) 2-(2-phenylethenyl)imidazoles were synthesized in
Stereoselective C(2)-Vinylation of 1-Substituted
Imidazoles with 3-Phenyl-2-propynenitrile
Boris A. Trofimov,* Lyudmila V. Andriyankova,
Kseniya V. Belyaeva, Anastasiya G. Mal’kina,
Lina P. Nikitina, Andrei V. Afonin, and Igor A. Ushakov
A. E. FaVorsky Irkutsk Institute of Chemistry, Siberian
Branch, Russian Academy of Sciences, 1 FaVorsky Strausse,
664033, Irkutsk, Russia
boris_trofimoV@irioch.irk.ru
ReceiVed July 1, 2008
First examples of direct vinylation of 1-substituted imidazoles
at the 2-position of the imidazole nucleus are described.
1-Substituted imidazoles 1a-e are C(2)-vinylated with
3-phenyl-2-propynenitrile (2) at room temperature without
catalyst and solvent to afford 3-(1-organyl-1H-imidazol-2-
yl)-3-phenyl-2-propenenitriles 3a-e, mainly (c.a. 95%) as
(Z)-isomers, in 56-88% yield. The reaction is likely to
involve the zwitterionic intermediates, which prototropically
isomerizes to imidazole carbene and eventually undergoes
the selective 3,2-shift of the functionalized vinyl substituent.
(8) Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Drugs 1978,
16, 387–417.
(9) (a) Niwano, Y.; Seo, A.; Kanai, K.; Hamaguchi, H.; Uchida, K.;
Yamaguchi, H. Antimicrob. Agents Chemother. 1994, 38, 2204–2206. (b) Santo,
R. Di.; Tafi, A.; Costi, R.; Botta, M.; Artico, M.; Corelli, F.; Forte, M.;
Caporuscio, F.; Angiolella, L.; Palamara, A. T. J. Med. Chem. 2005, 48, 5140–
5153.
(10) Brimblecombe, R. W.; Duncan, W. A. M.; Durant, G. J.; Emmett, J. C.;
Gannellin, C. R.; Parsons, M. E. J. Int. Med. Res. 1975, 3, 86–92.
(11) Pathan, M. Y.; Paike; V, V.; Pachmase, P. R.; More, S. P.; Ardhapure,
S. S.; Pawar, R. P. ArkiVoc 2006, Part (xv), 205–210.
(12) (a) Wilson and GisVold’s Textbook of Organic Medicinal and Pharma-
ceutical Chemistry, 10th ed; Delgado, J. N., Remers, W. A., Eds.; Lippincott-
Raven: Philadelphia, PA, 1998. (b) Coura, J. R. S.; de Castro, L. Mem. Inst.
Oswaldo Cruz 2002, 97, 3–24.
The imidazole nucleus is a common structural unit of
important biomolecules such as biotin, essential amino acids
(histidine, histamine), and the pilocarpin alkaloids.1a,b Other
imidazole alkaloids exhibit antimicrobial, anticryptococcal, and
cytotoxic activities.1b,2 Imidazole derivatives include nitric oxide
(13) (a) Welton, T. Chem. ReV. 1999, 99, 2071–2083. (b) Forsyth, S. A.;
Pringle, J. M.; MacFarlane, D. R. Aust. J. Chem. 2004, 57, 113–119. (c) Rahman,
T.; Fukuyama, T.; Ryu, I.; Suzuki, K.; Yonemura, K.; Hughes, P. F.; Nokihara,
K. Tetrahedron Lett. 2006, 47, 2703–2706. (d) Xu, J.-M.; Liu, B.-K.; Wu, W.-
B.; Qian, C.; Wu, Q.; Lin, X.-F. J. Org. Chem. 2006, 71, 3991–3993.
(14) (a) Bourissou, D.; Guerret, O.; Gabai, F. P.; Bertrand, G. Chem. ReV.
2000, 100, 39–91. (b) Nair, V.; Rajesh, C.; Vinod, A. U.; Bindu, S.; Sreekanth,
A. R.; Mathen, J. S.; Balagopal, L. Acc. Chem. Res. 2003, 36, 899–907. (c)
Nair, V.; Menon, R. S.; Sreekanth, A. R.; Abhilash, N.; Biju, A. T. Acc. Chem.
Res. 2006, 39, 520–530. (d) Marion, N.; Diez-Gonzalez, S.; Nolan, S. P. Angew.
Chem. 2007, 46, 2988–3000.
synthase3 and 5-lipoxygenase inhibitors,2,4 substances with
1b,5
CB1
and VEGF receptors I and II,1b,6 and neuropeptide Y
antagonistic activities.1b,7 Variously functionalized imidazoles
(1) (a) Grimmett, M. R. ComprehensiVe Heterocyclic Chemistry II; Katritsky,
A. R., Scriven, E. F. V., Eds.; Pergamon: Oxford, 1966; Vol. 3, pp 77-220. (b)
Bellina, F.; Cauteruccio, S.; Rossi, R. Tetrahedron 2007, 63, 4571–4624.
(2) De Luca, L. Curr. Med. Chem. 2006, 13, 1–23.
(3) Sennequier, N.; Wolan, D.; Stuehr, D. J. Biol. Chem. 1999, 274, 930–
938.
(15) (a) Ding, H.; Ma, C.; Yang, Y.; Wang, Y. Org. Lett. 2005, 7, 2125–
2127. (b) Trofimov, B. A.; Andriyankova, L. V.; Mal’kina, A. G.; Belyaeva,
K. V.; Nikitina, L. P.; Baikalova, L. V. MendeleeV Commun. 2007, 17, 237–
238.
(4) (a) Mano, T.; Stevens, R. W.; Ando, K.; Nakao, K.; Okumura, Y.;
Sakakibara, M.; Okumura, T.; Tamura, T.; Miyamoto, K. Bioorg. Med. Chem.
2003, 11, 3879–3887. (b) Mano, T.; Okumura, Y.; Sakakibara, M.; Okumura,
T.; Tamura, T.; Miyamoto, K.; Stevens, R. W. J. Med. Chem. 2004, 47, 720–
725.
(5) (a) Hunkeler, W.; Mohler, H.; Pierri, L.; Polc, P.; Bonetti, E. P.; Cumin,
R.; Schafinner, R.; Haefely, W. Nature 1981, 290, 514–516. (b) Dyck, B.;
Goodfellow, V. S.; Philips, T.; Grey, J.; Haddach, M.; Rowbotton, M.; Naeve,
G. S.; Brown, B.; Saunders, J. Bioorg. Med. Chem. Lett. 2004, 10, 1115–1154.
(6) Kiselyov, A. S.; Semenova, M.; Semenov, V. V. Bioorg. Med. Chem.
Lett. 2006, 16, 1440–1444.
(16) Rotenberg, A. S.; Panzer, H. P.; Schmitt, J. L.; Card, R. J. Preparation
of 2-vinylimidazoles by dehydrogenation of 2-ethylimidazoles and 2-ethylimi-
dazolines. Patent 379608, US, 1983.
(17) (a) Lawson, J. K. J. Am. Chem. Soc. 1953, 75, 3398–3400. (b)
Kolesnikov, G. S. Synthesis of Vinyl deriVatiVes of aromatic and heteroaromatic
compounds; Korshak, V. V., Ed.; Akad. Nauk SSSR: Moscow, 1960; pp 244-
246 (in Russian).
(18) Ohta, S.; Matsukawa, M.; Ohashi, N.; Nagayama, K. Synthesis 1990,
78–81.
(19) McNab, H.; Thornley, C. J. Chem. Soc., Perkin Trans. 1 1997, 2203–
2209.
(7) Blum, C. A.; Zheng, X.; De Lombaert, S. J. Med. Chem. 2004, 47, 2318–
2325.
(20) Popov, I. I.; Narezhnaya, Z. N.; Zubenko, A. A. Khim. Geterotsikl. Soed.
1978, 1104–1107.
10.1021/jo801240x CCC: $40.75
Published on Web 10/17/2008
2008 American Chemical Society
J. Org. Chem. 2008, 73, 9155–9157 9155